$FRENCKEN GROUP LIMITED(E28.SI)$Still going strong... 🚀

$MEDTECS INTERNATIONAL CORP LTD(546.SI)$Medtecs is big winner in this pandemic yearhttps://www.theedgesingapore.com/billion-dollar-club/billion-dollar-club-2021/medtecs-big-winner-pandemic-year

$Nanofilm(MZH.SI)$https://links.sgx.com/1.0.0/corporate-announcements/D6VIVO73TDX60Q52/ad4605c0556bc5181d8811409c928e6d6c8694ba45f4b768eabf44b80e38514a

$Nanofilm(MZH.SI)$https://links.sgx.com/1.0.0/corporate-announcements/W8R1EJNNQ0URWDQR/60443256698b9105545cd9fddd8b6a7a6675967a70f82d55f646c94b2a065ed5Yes... Now everything looks clearer...

$MEDTECS INTERNATIONAL CORP LTD(546.SI)$"There isn't much in this virus sequence suggesting it should be very mild," he said.Even if Omicron caused milder symptoms on average, the total toll of hospitalisations and deaths would be greater if it is much more infectious and better at escaping human immune protection.https://www.straitstimes.com/world/what-we-know-about-omicron-the-covid-19-variant-that-has-sparked-global-alarm

$Nanofilm(MZH.SI)$PURCHASE OF PROPERTY AT 11 TAI SENG DRIVE SINGAPORE The Board of Directors (the “Board”) of Nanofilm Technologies International Limited (the “Company”, and together with its subsidiaries, the “Group”) refers to the Company’s announcement dated 9 April 2021 in relation to the Company’s purchase of the property at 11 Tai Seng Drive Singapore 535226 (the “Property”). The Board is pleased to announce that the Company’s purchase of the Property has been completed today. The Property will serve as the Company’s headquarters for its operations in Singapore. With an expanded gross floor area of approximately 110,063 square feet, the Property is intended to meet the Group’s present business and future expansion needs. The Property will als

More than ever, Temasek is now actively acquiring more potential companies like AEM to nurture further... look at the rate Grab grows when it was still competing under an Uber dominated sg market ..

$Humanigen, Inc.(HGEN)$NIH Advances ACTIV-5/BET-B Trial Evaluating Lenzilumab from a Phase 2 Exploratory Study to a Phase 2/3 Study for the Treatment of COVID-19ACTIV-5/BET-B trial amended in the context of Humanigen’s positive Phase 3 lenzilumab LIVE-AIR studyPrimary endpoint focuses on survival without ventilation by day 28 in patients with baseline C-reactive protein (CRP) levels less than 150 mg/LStudy modification may enable Humanigen to use ACTIV-5/BET-B as a confirmatory study to support a future Biologics License Application (BLA)Approximately half of the 400 patients are already enrolled in ACTIV-5/BET-B

$Robinhood Markets, Inc.(HOOD)$[开心] 

The Philippines will likely face a “serious surge” of COVID-19 infections should the Omicron variant enter the country’s bordershttps://newsinfo.inquirer.net/1527526/serious-surge-of-infections-likely-if-omicron-enters-ph-octa-research

$Medtecs Intl(546.SG)$First person dies from Omicron variant in United Kingdomhttps://www.reuters.com/world/uk/britain-says-omicron-spreading-phenomenal-rate-2021-12-13/